Changes in lower urinary tract symptoms after prostate brachytherapy

Journal of Contemporary Brachytherapy

Volumn 3, Issue 3, 2011, Pages 115-120

  Jacobs, Bruce L ^a   Smith, Ryan P ^a   Beriwal, Sushil ^a   Benoit, Ronald M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Cesium 131; EPIC; Quality of life

Indexed keywords

CESIUM 131;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; HEALTH SURVEY; HEMATURIA; HUMAN; LONGITUDINAL STUDY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OBSTRUCTIVE UROPATHY; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; SCORING SYSTEM; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

EID: 80053452042     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2011.24816     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Cesaretti JA, Stone NN, Skouteris VM et al. Brachytherapy for the treatment of prostate cancer. Cancer J 2007; 13: 302-312.
3. Joseph J, Al-Qaisieh B, Ash D et al. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int 2004; 94: 1235-1238. (Pubitemid 40052084)
4. Grimm PD, Blasko JC, Sylvester JE et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 31-40. (Pubitemid 32758858)
5. Zelefsky MJ, Hollister T, Raben A et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261-1266. (Pubitemid 30421178)
6. Penson DF, Litwin MS, Aaronson NK. Health related quality of life in men with prostate cancer. J Urol 2003; 169: 1653-1661. (Pubitemid 36443466)
7. van Gellekom MP, Moerland MA, van Vulpen M et al. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys 2005; 63: 772-780. (Pubitemid 41400065)
8. Ash D, Bottomley D, Al-Qaisieh B et al. A prospective analysis of long-term quality of life after permanent I-125 bra - chytherapy for localized prostate cancer. Radiother Oncol 2007; 84: 135-139. (Pubitemid 47284527)
9. Talcott JA, Manol J, Clark JA et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21: 3979-3986. (Pubitemid 46606212)
10. Anderson JF, Swanson DA, Levy LB et al. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology 2009; 74: 601-605.
11. Aaltomaa SH, Kataja VV, Lahtinen T et al. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy - morbidity and outcome results. Radiother Oncol 2009; 91: 213-216.
12. Vordermark D, Noe M, Markert K et al. Prospective evaluation of quality of life with I125: importance of baseline symptoms and of prostate-V150. Radiother Oncol 2009; 91: 217-224.
13. Gellum DY, Potters L, Ashley R et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999; 45: 59-67. (Pubitemid 29380075)
14. Brown D, Colonias A, Miller R et al. Urinary morbidity with a modified peripheral loading technique of transperineal (125) i prostate implantation. Int J Radiat Oncol Biol Phys 2000; 47: 353-360. (Pubitemid 30236375)
15. Wei JT, Dunn RL, Litwin MS et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905.
16. Barry MJ, Fowler FJ Jr, O'Leary M et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-1557.
17. IsoRay Medical, Inc, CS-1 131Cs product information sheet and company web site. www.isoray.com. Accessed June 8, 2011.
18. Wallner K, Merrick G, True L et al. I-125 versus Pd-103 for lowrisk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2005; 11: 385-389. (Pubitemid 41725729)
19. Niehaus A, Merrick GS, Butler WM et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 64: 136-143. (Pubitemid 41831220)
20. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
21. Greene FL, Page DL, Fleming ID et al. In: AJCC Cancer Staging Manual, 6th ed. Springer, New York 2002; 309-316.